PDCD1 and cancer: Numerous studies have demonstrated that the use of PD-1/PD-L1 inhibitors alone in the treatment of various types of cancer patients is associated with a significantly elevated risk of irAEs, with this incidence typically reaching 20% to 30% (33–35), including risks associated with drug toxicity-related mortality and inflammatory responses in target organs (36, 37).